GlassScriptPhysician profile
Todd A Brockman
NPI 1730187907
$1,930.01
in general payments reported to CMS, 2019-2025
18 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $105 · 2021: $145 · 2022: $215 · 2023: $358 · 2024: $492 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $403.59 | 2019-2025 | Cequa |
| Alcon Vision LLC | $205.87 | 2019-2023 | Total30, Lensx |
| Bausch & Lomb Americas INC. | $205.40 | 2023-2025 | Miebo, Xiidra |
| Abbvie INC. | $192.54 | 2022-2025 | Durysta |
| Amgen INC. | $173.14 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $126.34 | 2019-2023 | |
| Horizon Therapeutics Plc | $113.60 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $112.16 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $86.56 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $82.24 | 2024-2025 | Xdemvy |
| Allergan, INC. | $78.74 | 2019-2021 | |
| Rxsight INC | $42.85 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Enterprises LLC | $31.98 | 2019 | |
| Thea Pharma INC. | $24.54 | 2023 | Iyuzeh |
| The Cameron-Ehlen Group, INC. | $22.59 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $14.28 | 2024 | Tecnis Simplicity |
| Ocular Therapeutix, INC. | $13.59 | 2023 | Dextenza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Brockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.